Weight Management

While incretin-based antiobesity medications are the optimal treatment for some, there are other less costly approaches that can support weight loss success, this author says.

The dual GIP/GLP-1 mimetic is available by prescription for adults with obesity or overweight with comorbidities and Lilly is offering a savings card program.

The 5 leading advocacy groups said the safety of people with obesity is at risk and called on the FDA to change clinical trial inclusion requirements and expedite labeling changes.

An obesity specialist discusses the importance of using a weight-first approach when educating patients about obesity's role in the development and worsening of hypertension.

From highest percentage of children with obesity to lowest percentage of adults with hypercholesterolemia, see how obesity hits home in our new slideshow.

The second GLP-1 mimetic-based drug approved for chronic weight management, tirzepatide may outperform semaglutide, the first.

Your daily dose of the clinical news you may have missed.

Tirzepatide could help individuals who lose weight with lifestyle change to maintain and augment that loss, a well known challenge among persons with obesity.

Your daily dose of the clinical news you may have missed.

The 2 highest doses of tirzepatide were ranked most likely to be effective for weight management in persons without diabetes, followed by semaglutide 2.4 mg.